The 2 references without contexts in paper Andrey Pavlysh Vladislavovich, Aleksei Kolbin Sergeevich, Roman Gapeshin Andreevich, Stanislav Malyshev Mikhailovich, Андрей Павлыш Владиславович, Алексей Колбин Сергеевич, Роман Гапешин Андреевич, Станислав Малышев Михайлович (2015) “Причины сложности проведения фармакоэкономического анализа для орфанных лекарств. Пути решения // REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS” / spz:neicon:pharmacoeconomics:y:2015:i:2:p:3-10

13
Drummond M., Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014; 15: 335-340.
(check this in PDF content)
27
Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: A flood of orphan drugs and abuses? Am J Law Med. 2005; 31 (2-3): 365-380.
(check this in PDF content)